Quick Take
CureVac (CVAC) intends to raise $200 million from the sale of its common stock in an IPO, plus another $118 million from a concurrent private placement, according to an amended registration statement.
The company is advancing a number of drug development and gene therapy programs for large and rare diseases.
CVAC says its Phase 3 trial for a Covid-19 vaccine will publish results in Q4 2020 and the IPO enjoys significant investor support, so the IPO is intriguing.
Company & Technology
Tubingen, Germany-based CureVac was founded to create mRNA-mediated treatment